ArticleArchives of microbiology2025
Characterization of the antifungal activity of the bacterial isolate Bacillus velezensis TCG15.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated genomic and metabolomic analysis reveals the biocontrol potential of endophytic Bacillus velezensis NS13 against Fusarium species in Lonicera macranthoides.BMC microbiology · 2026Article
- Integrating genomics and targeted metabolite profiling to elucidate disease-suppression mechanisms ofCurrent research in microbial sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bacillus velezensis TCG15 is a bacterial isolate from soil that shows antifungal activity against Aspergillus spp. and Candida spp. This study aimed to characterize its antifungal activity. TCG15 produces cyclic lipopeptides (cLPs), including surfactin A, plipastatin, and bacillomycin L. We obtained the complete sequence of the operon encoding nonribosomal peptide synthetase for bacillomycin L biosynthesis, bmyL operon (bmyLDABC), using genome analysis of TCG15. The bmyLD gene-disrupted mutant did not produce bacillomycin L, plipastatin, or surfactin A. The mutant showed no antifungal activity, indicating an essential role of cLPs. Among the cLPs, bacillomycin L was identified as the key antifungal compound. This activity was enhanced by surfactin A, which showed no antifungal activity alone. These findings suggested that the synergistic interaction between bacillomycin L and surfactin A contributed to the antifungal activity of TCG15.
Indexed as
Identifiers
40445208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.